UNITAID can address HCV/HIV co-infection
In the fi rst days of March, the governing body of UNITAID, the organisation fi nanced mainly through a levy on air tickets, will decide on a new 4-year strategy. A 5-year evaluation 1 praised UNITAID's success ful "market impact" model for improving access to HIV, tuberculosis, and malaria products through lower ing prices, improving supply, or introducing new products. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.
Worldwide, an estimated 4-5 million people are HCV/HIV co-infected.
2 HCV is a leading cause of death in people with HIV in western settings and causes substantial morbidity and mortality in the many co-infected people in lowincome and middle-income countries. HIV acceler ates HCV progression, and HCV co-infection is associated with higher rates of all-cause, liver-related, and AIDS-related death. 3, 4 Access to treatment with pegylated interferon alfa and ribavirin is extremely limited in low-resource settings owing to the regimen's complexity, duration (48 weeks), and cost (up to US$30 000). Outcomes in low-income and middleincome countries are similar to those reported in high-income countries; sustained virological response for co-infection can be as high as 60% depending on genotype. 
